Pusic I, Miklos D, Cutler C, et al. Ibrutinib for chronic graft-versus-host disease after failure of frontline corticosteroids: results of a multicenter open-label phase 2-study. EHA 2017, S492.
Sekseverschillen in ernstige bijwerkingen van immuuntherapie, targeted therapie of chemotherapie
mei 2022 | Immuuntherapie, Leukemie, Longoncologie, Maag-darm-leveroncologie